Literature DB >> 23350702

Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes.

Muna Sunni1, Melena D Bellin, Antoinette Moran.   

Abstract

OBJECTIVE: To examine whether insulin requirements and diabetes control differ between adolescents and adults with cystic fibrosis related diabetes (CFRD).
METHODS: All CFRD patients on insulin therapy seen at the University of Minnesota outpatient clinic from 1 January 2011 to 1 June 2012 were identified. Hemoglobin A1c (HbA1c) levels obtained during this period were averaged for each patient, and the most recent outpatient insulin dose was obtained. In addition, retrospective chart review was performed in order to obtain longitudinal data on insulin requirements during the transition from adolescence to adulthood.
RESULTS: Eighteen youth aged 14-19 yr and 137 adults aged 20-67 yr were identified to be currently on insulin therapy. The average insulin dose was 0.38 ± 0.29 units/kg/d for adolescents and 0.46 ± 0.30 units/kg/d for adults (p = 0.20). In adults, insulin doses were significantly higher in transplant recipients: Tx = 0.58 ± 0.29, no Tx = 0.43 ± 0.30 (p = 0.005). Average HbA1c was 6.9 ± 2.1% in youth and 6.9 ± 1.5% in adults (p = 0.35). There were no changes in the insulin dosage when adolescents transitioned to adulthood with diabetes were not on higher doses of insulin compared to when they were adolescents with diabetes.
CONCLUSION: Modest insulin requirements suggest the persistence of endogenous insulin secretion in both youth and adults with CFRD. In adolescents, residual endogenous insulin secretion likely compensates for the insulin resistance during puberty, keeping insulin requirements low.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23350702      PMCID: PMC3753224          DOI: 10.1111/pedi.12014

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  8 in total

1.  ISPAD clinical practice consensus guidelines 2009 compendium. Introduction.

Authors:  Ragnar Hanas; Kim C Donaghue; Georgeanna Klingensmith; Peter G F Swift
Journal:  Pediatr Diabetes       Date:  2009-09       Impact factor: 4.866

2.  Insulin resistance during puberty: results from clamp studies in 357 children.

Authors:  A Moran; D R Jacobs; J Steinberger; C P Hong; R Prineas; R Luepker; A R Sinaiko
Journal:  Diabetes       Date:  1999-10       Impact factor: 9.461

3.  Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy.

Authors:  Susanna Wiegand; Klemens Raile; Thomas Reinehr; Sabine Hofer; Andrea Näke; Wolfgang Rabl; Reinhard W Holl
Journal:  Eur J Endocrinol       Date:  2008-04       Impact factor: 6.664

4.  Basal insulin and total daily insulin dose in children with type 1 diabetes using insulin pumps.

Authors:  Ewa Pańkowska; Agnieszka Szypowska; Maria Lipka
Journal:  Pediatr Diabetes       Date:  2008-06       Impact factor: 4.866

5.  Insulin doses in children using conventional therapy for insulin dependent diabetes.

Authors:  N Kerouz; R el-Hayek; R Langhough; M J MacDonald
Journal:  Diabetes Res Clin Pract       Date:  1995-08       Impact factor: 5.602

6.  Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis.

Authors:  Scott M Blackman; Stephanie Hsu; Lori L Vanscoy; J Michael Collaco; Sarah E Ritter; Kathleen Naughton; Garry R Cutting
Journal:  J Clin Endocrinol Metab       Date:  2009-01-06       Impact factor: 5.958

7.  Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.

Authors:  Antoinette Moran; Carol Brunzell; Richard C Cohen; Marcia Katz; Bruce C Marshall; Gary Onady; Karen A Robinson; Kathryn A Sabadosa; Arlene Stecenko; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

8.  Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.

Authors:  Antoinette Moran; Jordan Dunitz; Brandon Nathan; Asad Saeed; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2009-06-19       Impact factor: 19.112

  8 in total
  2 in total

1.  Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.

Authors:  Rodrigo Abensur Athanazio; Luiz Vicente Ribeiro Ferreira da Silva Filho; Alberto Andrade Vergara; Antônio Fernando Ribeiro; Carlos Antônio Riedi; Elenara da Fonseca Andrade Procianoy; Fabíola Villac Adde; Francisco José Caldeira Reis; José Dirceu Ribeiro; Lídia Alice Torres; Marcelo Bicalho de Fuccio; Matias Epifanio; Mônica de Cássia Firmida; Neiva Damaceno; Norberto Ludwig-Neto; Paulo José Cauduro Maróstica; Samia Zahi Rached; Suzana Fonseca de Oliveira Melo
Journal:  J Bras Pneumol       Date:  2017 May-Jun       Impact factor: 2.624

Review 2.  Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis.

Authors:  Vittorio Ferrari; Vito Terlizzi; Stefano Stagi
Journal:  J Clin Med       Date:  2022-07-13       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.